These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 26409125)

  • 41. Clinical utility of topiramate extended-release capsules (USL255): Bioequivalence of USL255 sprinkled and intact capsule in healthy adults and an in vitro evaluation of sprinkle delivery via enteral feeding tubes.
    Clark AM; Pellock JM; Holmay M; Anders B; Cloyd J
    Epilepsy Behav; 2016 Apr; 57(Pt A):105-110. PubMed ID: 26943947
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Topiramate extended-release (Trokendi XR) for epilepsy.
    Med Lett Drugs Ther; 2013 Oct; 55(1428):87-8. PubMed ID: 24165709
    [No Abstract]   [Full Text] [Related]  

  • 43. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy.
    Rosenfeld WE; Liao S; Kramer LD; Anderson G; Palmer M; Levy RH; Nayak RK
    Epilepsia; 1997 Mar; 38(3):324-33. PubMed ID: 9070595
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quetiapine extended-release versus immediate-release formulation: a positron emission tomography study.
    Mamo DC; Uchida H; Vitcu I; Barsoum P; Gendron A; Goldstein J; Kapur S
    J Clin Psychiatry; 2008 Jan; 69(1):81-6. PubMed ID: 18312041
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bioavailability of triple-bead mixed amphetamine salts compared with a dose-augmentation strategy of mixed amphetamine salts extended release plus mixed amphetamine salts immediate release.
    Ermer JC; Shojaei A; Pennick M; Anderson CS; Silverberg A; Youcha SH
    Curr Med Res Opin; 2007 May; 23(5):1067-75. PubMed ID: 17519073
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term tolerability and safety of lamotrigine extended-release: pooled analysis of three clinical trials.
    Biton V; Shneker BF; Naritoku D; Hammer AE; Vuong A; Caldwell PT; Messenheimer JA
    Clin Drug Investig; 2013 May; 33(5):359-64. PubMed ID: 23475541
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Once-daily dosing is appropriate for extended-release divalproex over a wide dose range, but not for enteric-coated, delayed-release divalproex: evidence via computer simulations and implications for epilepsy therapy.
    Reed RC; Dutta S; Liu W
    Epilepsy Res; 2009 Dec; 87(2-3):260-7. PubMed ID: 19892524
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intravenous topiramate: safety and pharmacokinetics following a single dose in patients with epilepsy or migraines taking oral topiramate.
    Clark AM; Kriel RL; Leppik IE; White JR; Henry TR; Brundage RC; Cloyd JC
    Epilepsia; 2013 Jun; 54(6):1106-11. PubMed ID: 23586686
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
    Packer M; Lukas MA; Tenero DM; Baidoo CA; Greenberg BH;
    Am J Cardiol; 2006 Oct; 98(7A):39L-45L. PubMed ID: 17023231
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
    Jenner P; Könen-Bergmann M; Schepers C; Haertter S
    Clin Ther; 2009 Nov; 31(11):2698-711. PubMed ID: 20110012
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine.
    Britzi M; Perucca E; Soback S; Levy RH; Fattore C; Crema F; Gatti G; Doose DR; Maryanoff BE; Bialer M
    Epilepsia; 2005 Mar; 46(3):378-84. PubMed ID: 15730535
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years.
    Mikaeloff Y; Rey E; Soufflet C; d'Athis P; Echenne B; Vallée L; Bouhours P; Grinspan A; Dulac O; Pons G; Chiron C
    Epilepsia; 2004 Nov; 45(11):1448-52. PubMed ID: 15509246
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics and safety of adjunctive topiramate in infants (1-24 months) with refractory partial-onset seizures: a randomized, multicenter, open-label phase 1 study.
    Manitpisitkul P; Shalayda K; Todd M; Wang SS; Ness S; Ford L
    Epilepsia; 2013 Jan; 54(1):156-64. PubMed ID: 23157581
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Self-reported sedation profile of quetiapine extended-release and quetiapine immediate-release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study.
    Riesenberg RA; Baldytcheva I; Datto C
    Clin Ther; 2012 Nov; 34(11):2202-11. PubMed ID: 23059166
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Simulations of topiramate dosage recommendations for poor compliance events.
    Methaneethorn J; Charoenchokthavee W
    Eur J Clin Pharmacol; 2022 Nov; 78(11):1843-1850. PubMed ID: 36121498
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Simulation of the effect of patient nonadherence on plasma concentrations of carbamazepine from twice-daily extended-release capsules.
    Garnett WR; McLean AM; Zhang Y; Clausen S; Tulloch SJ
    Curr Med Res Opin; 2003; 19(6):519-25. PubMed ID: 14594524
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Extended-release formulations for the treatment of epilepsy.
    Bialer M
    CNS Drugs; 2007; 21(9):765-74. PubMed ID: 17696575
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Once-daily lamotrigine extended release for epilepsy management.
    Rheims S; Ryvlin P
    Expert Rev Neurother; 2009 Feb; 9(2):167-73. PubMed ID: 19210192
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
    Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
    Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.
    Battegay M; Arasteh K; Plettenberg A; Bogner JR; Livrozet JM; Witt MD; Mossdorf E; Yong CL; Zhang W; Macha S; Berger F; Stern J; Robinson P; Quinson AM
    Clin Ther; 2011 Sep; 33(9):1308-20. PubMed ID: 21872931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.